Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Designing Herpes Viruses as Oncolytics.

Peters C, Rabkin SD.

Mol Ther Oncolytics. 2015;2. pii: 15010.

2.

Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy.

Farrar CT, Buhrman JS, Liu G, Kleijn A, Lamfers ML, McMahon MT, Gilad AA, Fulci G.

Radiology. 2015 Jun;275(3):746-54. doi: 10.1148/radiol.14140251.

3.

Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.

Kuruppu D, Brownell AL, Shah K, Mahmood U, Tanabe KK.

Cancer Res. 2014 Aug 1;74(15):4111-21. doi: 10.1158/0008-5472.CAN-13-3472.

4.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.

Neuro Oncol. 2014 Aug;16(8):1057-66. doi: 10.1093/neuonc/not317.

5.

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.

Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12006-11. doi: 10.1073/pnas.1307935110.

6.

Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.

Neoplasia. 2013 Jun;15(6):591-9.

7.
8.

Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.

Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL.

Stem Cells Transl Med. 2012 Apr;1(4):322-32. doi: 10.5966/sctm.2011-0035.

9.

Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.

Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K.

Mol Ther. 2013 Jan;21(1):68-77. doi: 10.1038/mt.2012.175.

10.

Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT Jr.

Neurosurgery. 2012 Sep;71(3):741-8; discussion 748. doi: 10.1227/NEU.0b013e318260fd73.

11.

Back to BAC: the use of infectious clone technologies for viral mutagenesis.

Hall RN, Meers J, Fowler E, Mahony T.

Viruses. 2012 Feb;4(2):211-35. doi: 10.3390/v4020211. Review.

12.

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL.

J Natl Cancer Inst. 2012 Jan 4;104(1):42-55. doi: 10.1093/jnci/djr509.

13.

Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.

Yamada S, Kuroda T, Fuchs BC, He X, Supko JG, Schmitt A, McGinn CM, Lanuti M, Tanabe KK.

Cancer Gene Ther. 2012 Mar;19(3):160-70. doi: 10.1038/cgt.2011.70.

14.

Herpesvirus BACs: past, present, and future.

Warden C, Tang Q, Zhu H.

J Biomed Biotechnol. 2011;2011:124595. doi: 10.1155/2011/124595. Review.

15.

Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.

Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL.

Gene Ther. 2010 Jun;17(6):805-10. doi: 10.1038/gt.2010.20.

16.

Cost-effective HRMA pre-sequence typing of clone libraries; application to phage display selection.

Pepers BA, Schut MH, Vossen RH, van Ommen GJ, den Dunnen JT, van Roon-Mom WM.

BMC Biotechnol. 2009 May 22;9:50. doi: 10.1186/1472-6750-9-50.

17.

Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD.

Cancer Res. 2009 Apr 15;69(8):3472-81. doi: 10.1158/0008-5472.CAN-08-3886.

18.

Design and application of oncolytic HSV vectors for glioblastoma therapy.

Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC.

Expert Rev Neurother. 2009 Apr;9(4):505-17. doi: 10.1586/ern.09.9. Review.

Items per page

Supplemental Content

Support Center